Alluvi, previously BI 4744, offers a notable development in weight management care. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates compelling results in patient trials, potentially https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/